Professor, Department of Urologic Surgery, Vanderbilt University Medical Center, A-1392, Medical Center North, Nashville, TN 37232, USA.
Ther Adv Urol. 2009 Oct;1(4):209-21. doi: 10.1177/1756287209350383.
The prevalence of overactive bladder (OAB) symptoms is considerable in both men and women and the impact on quality of life (QOL) is equally substantial. Ironically, despite nearly equal prevalence, OAB symptoms in men are infrequently treated, and often with medical therapies aimed at bladder outlet obstruction (BOO). In this review, we examine the pathophysiology of OAB and its evaluation in the context of benign prostatic hypertrophy and concomitant BOO. We then consider the efficacy and safety of individual therapeutic options for lower urinary tract symptoms in men, focusing on the mainstays of medical therapy: α-adrenergic blockers, 5-α reductase inhibitors, and antimuscarinic agents. Finally, we aim to comment on new therapeutic strategies and targets that may one day be available for the treatment of male OAB.
膀胱过度活动症（OAB）的症状在男性和女性中都相当普遍，对生活质量（QOL）的影响同样巨大。具有讽刺意味的是，尽管患病率几乎相等，但男性的 OAB 症状很少得到治疗，而且通常采用针对膀胱出口梗阻（BOO）的医学治疗方法。在这篇综述中，我们检查了 OAB 的病理生理学及其在良性前列腺增生和伴随的 BOO 中的评估。然后，我们考虑了男性下尿路症状的个别治疗选择的疗效和安全性，重点是医学治疗的主要方法：α-肾上腺素能阻滞剂、5-α 还原酶抑制剂和抗毒蕈碱药物。最后，我们旨在评论新的治疗策略和靶点，这些策略和靶点有朝一日可能可用于治疗男性 OAB。
